Citius Pharmaceuticals is trading 5.73% up at $0.78, with no clear company-specific announcement or reliable report directly explaining the August 14, 2026 move.

  • Available coverage instead points to prior LYMPHIR commercial momentum and an August 12 board appointment.
  • The broader market is modestly lower, so macro sentiment does not clearly account for the gain.